Abstract
The genotoxicity of fluoride in vivo in seven patients with osteoporosis was cytogenetically investigated. The patients were treated with fluoride‐containing formulations (disodium monofluorophosphate and sodium fluoride) for a period of 15 months up to 49 months. Fluoride intake ranged from 22.6‐33.9 mg F-/day and serum fluoride concentrations were between 0.1 mg F-/l and 0.2 mg F-/l. Peripheral blood lymphocytes of these patients were cultured in vitro and examined for chromosomal aberrations, micronuclei in cytokinesis‐blocked binucleated lymphocytes as well as cell cycle progression. When a comparison was made between patients' group and a matched control group, it was found that fluoride at the tested concentrations had no detectable genotoxic potential in human lymphocytes in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Philips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older. Bone 1988;9: 271–9.
Dempster W, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993;341: 797–801.
Duursma SA, Raymakers JA, Scheven BAA, Jansen PAF. Osteoporosis reviews in clinical gerontology 1993;3: 135–46.
Riggs BL. Fluoride revisited. Research and Clinical Forums 1993;15(1): 36–9.
Li Y, Dunipace AJ, Stooky GK. Genotoxic effects of fluoride: a controversial issue. Mutat Res 1988;195: 127–36.
Baylink DJ. Serum fluoride levels. In Primer on metabolic bone diseases and disorders of mineral metabolism. 1st ed. 170–1. Kelseyville, CA: American Society for Bone and Mineral Research, California, 1990.
Albanese R. Sodium fluoride and chromosome damage (in vitro human lymphocytes and in vivo micronucleus assays). Mutagenesis 1987;6: 497–9.
Kishi K, Tonomura A. Cytogenetic effects of sodium fluoride. Mutat Res 1984;130: 367(abstract).
Scott D, Roberts SA. Extrapolation from in vitro tests to human risk. Experience with sodium fluoride clastogenicity. Mutat Res 1987;189: 47–58.
Kaminsky LS, Mahoney MC, Leach J, Melius J, Miller MJ. Fluoride: benefits and risks of exposure. Crit Rev Oral Biol Med 1990;1(4): 268–81.
Zeiger E, Shelby MD, Witt KI. Genetic toxicity of fluoride. Environ Mol Mutagen 1993;21(4): 309–18.
Perry P, Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature (London) 1974;251: 156–68.
Glerum JH, van Dijk A, Klein SW. A new and improved gas chromatographic method for the determination of fluoride in plasma and feaces. Pharm Weekbl [Sci] 1984;6: 75–9.
Smith GE. Is fluoride a mutagen? Sci Tot Environ 1988;68: 79–96.
Thomson EJ, Kolanowski FM, Perry PE. The effect of fluoride on chromosome aberration and sister-chromatid exchange frequencies in cultured human lymphocytes. Mutation Res 1985;144: 89–92.
Carrano AV, Natarajan AT. Considerations for population monitoring using cytogenic techniques. ICPEMC Publication no14. Mutat Res 1988;204: 379–407.
Evans HJ, O'Riordan ML. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat Res 1975;31: 135–48.
Rich C, Feist E. The actions of fluoride on bone. In Vischer TL, ed. Fluoride in medicine. Bern: Huber, 1970: 70–87.
Duffery PH, Tratbar HC, Jarkowski TL. Giant cells in bone marrow of patients on high dose fluoride treatment. Ann Intern Med 1971;76: 745–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Asten, P., Darroudi, F., Natarajan, A.T. et al. Cytogenetic effects on lymphocytes in osteoporotic patients on long-term fluoride therapy. Pharm World Sci 20, 214–218 (1998). https://doi.org/10.1023/A:1008672220053
Issue Date:
DOI: https://doi.org/10.1023/A:1008672220053